Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFOXIRI + bevacizumab
- Development stage
- Unknown
- Lead developer
- University of Pisa
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
FOLFOXIRI + bevacizumab is a combination chemotherapy and targeted therapy regimen used primarily as first-line treatment for metastatic colorectal cancer. The regimen consists of four chemotherapeutic agents—5-fluorouracil (a pyrimidine analog antimetabolite), folinic acid (leucovorin, which enhances the effect of 5-FU), oxaliplatin (a platinum-based DNA crosslinker), and irinotecan (a topoisomerase I inhibitor)—combined with bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). Bevacizumab inhibits angiogenesis by blocking VEGF-A, thereby reducing tumor blood supply. This combination has demonstrated improved progression-free survival and overall survival compared to doublet regimens plus bevacizumab in phase III trials. The regimen is associated with increased response rates but also higher rates of grade 3/4 toxicities such as neutropenia and diarrhea[1][6][3].
- Brand names
- Avastin
- Other names
- folinic acid-fluorouracil-oxaliplatin-irinotecan-bevacizumableucovorin-fluorouracil-oxaliplatin-irinotecan-bevacizumab
02
Targets
Beyond the preview
Go deeper on FOLFOXIRI + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFOXIRI + bevacizumab.